Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:G01N33/569

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/233147INERT CARRIER ESCHERICHIA COLI AND POTENTIAL USE THEREOF
WO 26.11.2020
Int.Class C12N 1/20
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
1Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
20Bacteria; Culture media therefor
Appl.No PCT/CN2020/071625 Applicant YANGZHOU UNIVERSITY Inventor ZHU, Guoqiang
Disclosed are an inert carrier Escherichia coli and the use thereof, wherein the inert carrier Escherichia coli has been deposited in the China General Microbiological Culture Collection Center (CGMCC), with a deposit address of Beijing, China, a deposit number of CGMCC No. 17339, a deposit date of March 18, 2019, a classification name of Escherichia coli, and a strain code of SE1. The Escherichia coli does not cause any macroscopic agglutination reaction with various chicken sera of different genetic backgrounds, i.e., does not generate a non-specific agglutination reaction with different kinds of chicken sera, has the properties of being expressed and displayed on the surface a specific antigen protein, and is used as an inert carrier in an indirect agglutination test for detecting antigens or antibodies.
2.WO/2020/235607METHOD FOR DETECTING TARGET MOLECULE
WO 26.11.2020
Int.Class G01N 37/00
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
37Details not covered by any other group of this subclass
Appl.No PCT/JP2020/019992 Applicant TOPPAN PRINTING CO., LTD. Inventor HIRASE Takumi
This method for detecting a surface target molecule and an internal target molecule of a structure comprises steps for: bringing a liquid having a structure dispersed therein into contact with a well array having a plurality of wells so as to introduce the structure into the wells; bringing an encapsulation liquid into contact with the well array so as to cause the structure to be encapsulated within each of the wells; extracting content of the structure within each of the wells; detecting at least one type of surface target molecule present on the surface of the structure within each of the wells; and detecting at least one type of internal target molecule present inside the structure within each of the wells.
3.20200371100ASSAY METHODS FOR IMPROVED ANALYTE DETECTION
US 26.11.2020
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
Appl.No 16636795 Applicant ORASURE TECHNOLOGIES, INC. Inventor Graham YEARWOOD

Disclosed herein are assay methods, lateral flow assay test strips, and devices for improved analyte detection. Analyte binding to target is performed both in solution phase and with a target immobilized on a surface, resulting in improved analyte detection.

4.20200371110METHODS FOR IDENTIFYING AND TREATING HIV PERSISTENCE
US 26.11.2020
Int.Class G01N 33/66
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
66involving blood sugars, e.g. galactose
Appl.No 16961043 Applicant The Wistar Institute of Anatomy and Biology Inventor Mohamed ABDEL-MOHSEN

Methods for identifying or monitoring or treating HIV persistence or the development of an HIV-comorbidity in an HIV+ subject involve certain selected glycan dysregulations. In certain embodiments, hyposialylation in the total IgG glycome or total plasma glycome of an HIV+ subject during or after antiretroviral therapy is an indication of HIV persistence and can be predictive of developing co-morbidities. Methods of treating HIV persistence or preventing developing co-morbidities involves modifying or manipulating the selected glycan by administering therapeutic agents that will modify the levels of the selected glycan, a precursor thereof, or another component of its pathway.

5.WO/2020/236875MADCAM TARGETED IMMUNOTOLERANCE
WO 26.11.2020
Int.Class C07K 14/705
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
Appl.No PCT/US2020/033707 Applicant PANDION THERAPEUTICS, INC. Inventor HIGGINSON-SCOTT, Nathan
Methods and compounds for conferring site-specific or local immune privilege, such as targeting to a cell expressing MAdCAM. Disclosed herein are methods and therapeutic compounds that provide site-specific immune privilege. In some embodiments, the therapeutic compound comprises an engineered multi-specific compound, e.g., an engineered bi-specific molecule, e.g., an engineered bi-specific antibody molecule.
6.20200371029AUTOMATED IMMUNOANALYZER SYSTEM FOR PERFORMING DIAGNOSTIC ASSAYS FOR AUTOIMMUNE AND INFECTIOUS DISEASES
US 26.11.2020
Int.Class G01N 21/64
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
21Investigating or analysing materials by the use of optical means, i.e. using infra-red, visible or ultra-violet light
62Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
63optically excited
64Fluorescence; Phosphorescence
Appl.No 16940947 Applicant Hycor Biomedical, LLC Inventor Mark David Van Cleve

A quantitative method for diagnosing an autoimmune disease or an infectious disease comprising performing an automated diagnostic assay, comprising: incubating a capture reagent with a streptavidin-coated medium to form a solid phase complex, wherein the capture reagent is a biotinylated autoantigen or infectious disease antigen; washing the solid phase complex to remove excess capture reagent; incubating the solid phase complex with a serum sample to form an immune complex; washing the immune complex to remove any unbound sample; incubating the immune complex with a conjugate to create an immune-conjugate complex; washing the immune-conjugate complex to remove any unbound conjugate; introducing a substrate capable of generating a quantifiable response; and calibrating the response generated from introducing the substrate.

7.20200371099Triage biomarkers and uses therefor
US 26.11.2020
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
Appl.No 16065752 Applicant ImmuneXpress Pty Ltd Inventor Richard Bruce BRANDON

Disclosed are methods, apparatus, kits and compositions for determining the absence of a systemic bacterial infection (sepsis) in patients, particularly ones presenting to hospital emergency departments (ED) as outpatients, by measurement of the host immune response using peripheral blood. The are methods, apparatus, kits and compositions can be used in mammals for diagnosing, making treatment decisions, determining the next procedure or diagnostic test, or management of patients suspected of having an infection, including those presenting with fever or other signs of systemic inflammation. More particularly, peripheral blood RNA and protein biomarkers are disclosed that are useful for distinguishing between the host immune response to bacteria compared to the host immune response to other causes of systemic inflammation including trauma, burns, autoimmune disease, asthma, anaphylaxis, arthritis, obesity and viral infections. As such, the biomarkers are useful for distinguishing bacterial-associated systemic inflammatory response syndrome from non-bacterial systemic inflammation to provide clinicians with strong negative predictive value (>95%) so that sepsis can be excluded as a diagnosis in patients presenting to ED with clinical signs of systemic inflammation.

8.WO/2020/237044BACTERIOPHAGES FOR THE TREATMENT OF TUBERCULOSIS
WO 26.11.2020
Int.Class A61K 35/76
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
Appl.No PCT/US2020/033985 Applicant UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION Inventor HATFULL, Graham
The invention provides a composition (e.g., pharmaceutical composition) comprising a combination of two or more phages, wherein the phages are two or more of: (a) phage D29; (b) phage Adephagia∆41∆43; (c) phage Fionnbharth∆47; (d) phage Fred313cpm-1; and (e) phage MuddyHRMN0052-1; and a pharmaceutically acceptable carrier. The invention provides a method of treating, reducing, or preventing a disease caused by Mycobacterium tuberculosis in a mammal comprising administering a pharmaceutical composition comprising a combination of two or more phages wherein the phages are two or more of: (a) phage D29; (b) phage Adephagia∆41∆43; (c) phage Fionnbharth∆47; (d) phage Fred313cpm-1; and (e) phage MuddyHRMN0052-1; and a pharmaceutically acceptable carrier. The composition can be administered alone or in combination with one or more antibiotics, wherein the length of treatment is reduced as compared to the length of treatment with one or more antibiotics alone.
9.WO/2020/233503DETECTION METHOD
WO 26.11.2020
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CN2020/090425 Applicant UNIVERSITY OF MACAU Inventor WONG, Hang Heng
Provided is a method for assessing cytotoxicity of a cytotoxic cell that includes culturing a plurality of the cytotoxic cells with a plurality of target cells in a microfluidic device and determining whether the cytotoxic cells have a cytotoxic effect on the target cells, such as by determining a cell count and/or status of the cytotoxic cells and/or the target cells. A kit and a system for use in the aforementioned method are also provided.
10.20200371098CHROMOGENIC MEDIUM FOR THE DETECTION AND IDENTIFICATION OF VANCOMYCIN RESISTANT ENTEROCOCCI AND METHOD THEREFOR
US 26.11.2020
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
Appl.No 16991502 Applicant BECTON DICKINSON AND COMPANY Inventor Susan Kircher

A microbe-specific medium, containing specific chromogenic substrates, for the detection of vancomycin-resistant enterococci in a biological sample, whereby both the detection and identification of vancomycin-resistant enterococci at the species level is achieved utilizing one sample and one test.